MDPHP is assumed to act generally like a potent norepinephrine-dopamine reuptake inhibitor (NDRI). Decreased re-uptake of norepinephrine and dopamine leads to increased concentrations of the two catecholamine neurotransmitters within the synaptic cleft, or gap in between neurons. The results of this inhibition is definitely an enhanced and extended